Stewardship

Our strategy aims to improve antibiotic stewardship by designing the right drug for the right bug

What is antibiotic stewardship


Antibiotic stewardship promotes the appropriate use of antibiotics to ultimately improve patient outcomes and reduce healthcare costs. The CDC estimates that 20-50% of antibiotics prescribed in the US are either unnecessary or inappropriate. Unnecessary or inappropriate use of antibiotics is one of the driving factors of antibiotic resistance. In addition, it puts patients at risk of serious adverse events and can contribute to excessive healthcare costs.

The CDC and Infectious Disease Society of America (IDSA) define antibiotic stewardship as providing patients with the optimal antibiotic at the right time, right dose, right site of infection and for the right duration.

The need for stewardship is driven by two factors: (1) increasing antibiotic resistance and (2) a lack of innovation in antibiotic development. In an attempt to reduce the emergence of resistance to new antibiotics, physicians have kept them in reserve for only severe cases. The issue with these new antibiotics is they have generally been broad-spectrum analogues of older antibiotics already in use. That is, these antibiotics are not necessarily the most appropriate or optimal drug for the infection and are more likely to promote resistance development.

Our approach to stewardship


Our approach to antibiotic development exemplifies antibiotic stewardship – creating the right drug for the right bug. We believe this is achievable because our new science allows us to develop new mechanism antibiotics, and because advances in bedside diagnostics are able to rapidly identify disease-causing pathogens. We therefore believe we can design antibiotics for a specific pathogen or infection, and reserve broad spectrum antibiotics for idiopathic infections. This approach serves to improve patient outcomes and reduce resistance development. Ultimately, we believe antibiotic stewardship provides an opportunity for high-volume use of our antibiotics, which may lead to commercial success.